Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis

Sponsor
Abbott (Industry)
Overall Status
Completed
CT.gov ID
NCT00091481
Collaborator
(none)
201
19
10.6

Study Details

Study Description

Brief Summary

To show non-inferiority in the incidence rates of elevated calcium-phosphorus product between two treatment groups: 1) a group having an initial dose based on baseline PTH (baseline iPTH/80) and 2) a group having a starting dose based on body weight (0.04 mcg/kg).

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
201 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
A Randomized, Active-Controlled, Double-Blind Multi-Center Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis
Study Start Date :
Jun 1, 2003

Outcome Measures

Primary Outcome Measures

  1. Incidence rate of at least two consecutive calcium-phosphorus product levels greater than 65. []

Secondary Outcome Measures

  1. Evaluate the number of days to achieve the first of 2 consecutive > or = 30% decreases from baseline in PTH []

  2. The incidence rate for hypercalcemia []

  3. The incidence rate for hyperphosphatemia []

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Stage V Chronic Kidney Disease

  • Patients on Hemodialysis requiring treatment for secondary hyperparathyroidism with vitamin D therapy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Errikos Dynan Hospital Ambelokipi Athens Greece 11526
2 General Hospital of Athens, "G.Gennimatas" Holargos Athens Greece 11527
3 General Hospital of Attica "Sismanoglio" Marousi Athens Greece 15126
4 "Hygeia" Diagnosis and Therapy Center Marousi Athens Greece 152 00
5 General Hospital of Melissia "Amalia Fleming" Melissia Athens Greece 15127
6 General Hospital of Voula Askilpieion Voula Athens Greece 16673
7 General Hospital of Heraklion Voutes, Heraklion Crete Greece
8 General Hospital Thessaloniki "Papanikolaou" Exohi Thessaloniki Greece 570 10
9 General Hospital of Veria Papagou Area Veria Greece
10 Blue Cross Clinic Athens Greece 11528
11 Evgenidio Clinic Athens Greece 11528
12 Regional General Hospital of Athens "Korgialeneio-Benakeio" Athens Greece
13 General University Hospital of Alexandroupolis Dragana Greece 68100
14 Regional General Hospital of Ioannina "Hatzikosta" Ioannina Greece 450 01
15 General University Hospital Ioannina Ioannina Greece 455 00
16 General Hospital of Nikea "Agios Panteleimon" Nikea, Piraeus 18454, Greece
17 General Hospital of Thessaloniki "Ahepa" Thessaloniki Greece
18 General Hospital of Thessaloniki "Hippokrateion" Thessaloniki Greece
19 General Hospital of Thessaloniki "Papageorgiou" Thessaloniki Greece

Sponsors and Collaborators

  • Abbott

Investigators

  • Study Director: Jin Tian, M.D., Abbott

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00091481
Other Study ID Numbers:
  • M01-367
First Posted:
Sep 13, 2004
Last Update Posted:
Sep 26, 2007
Last Verified:
Sep 1, 2007

Study Results

No Results Posted as of Sep 26, 2007